Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study.
Nicolas WillietAngelica PetrilloGaël S RothMichele GhidiniMila PetrovaJulien ForestierAnthony LopezAudrey ThoorLucie WeislingerFerdinando De VitaGilles ManceauJean Marc PhelipPublished in: Cancers (2021)
This retrospective study did not show any difference between GN and FFX as the first-line treatment in patients with LAPC.